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Finally, Whitfield implies it is important to determine
whether social factors or LD are responsible for the dif-
ferences in effects of ADH1B*47His in eastern Asia and
in Europe. Social factors can indeed be very important
in modifying risk associated with different genotypes.
For example, it will be difficult to determine the actual
risk associated with ADH variation in northern Africa
and the Middle East, since most populations in those
regions are Muslim and consumption of alcohol is pro-
scribed by their religion. However, we note that the rel-
evant “genetic” component is not strictly differences in
LD but differences in what haplotypes are present. A
site in the ADH cluster but not in LD with the ADH1B
Arg47His site could have an epistatic effect such that
only those chromosomes with particular alleles in cou-
pling account for the protective effect. Moreover, back-
ground genotype clearly differs at the population level
between eastern Asian populations and European pop-
ulations (e.g., Calafell et al. 1998) adding yet another
level of confounding on the path to understanding the
role of the ADH1B Arg47His polymorphism in risk of
alcoholism.
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Detecting Polymorphisms and Mutations in Candidate
Genes
To the Editor:
Currently, there is no consensus in the literature as to
the number and the nature of controls that should be
studied to distinguish between polymorphisms and dis-
ease-causing mutations (Bridge 1997). The quandary be-
comes particularly acute when we are trying to deter-
mine if a missense alteration in a candidate gene is
important (disease associated). How many control sam-
ples should be tested, and what other considerations
should go into the selection of controls? It is important
to consider and report the status, race or ethnic back-
ground, and sex (if appropriate) of controls. Further-
more, how many patients should be studied when one
is screening a gene for mutations? We have attempted
to address these concerns in this letter.
First, one needs to consider if the control subjects
could have the same disorder as the case subjects. Where
did the control subjects originate, and how were they
selected? The use of convenient control subjects (new-
born samples, unused diagnostic samples, etc.) may in-
advertently include individuals who are carriers or af-
fected. If one uses control subjects selected for a
particular study, they may or may not be appropriate
for a different study. When studying psychiatric disor-
ders, one needs to ensure that the controls do not have
undiagnosed problems. When studying late-onset dis-
eases, one needs to confirm that the control subjects are
past the age of onset.
Marchuk (1998) suggested typing controls from sim-
ilar racial, ethnic, and geographic backgrounds, since
allele frequencies can differ between groups. In the past,
ignoring this important tenet has caused some mutations
to be misclassified. The peripheral myelin protein 22
Thr118Met substitution was believed to be a mutation
in Charcot-Marie-Tooth disease, but was found to be a
Swedish polymorphism (Nelis et al. 1997). The fibrillin-
1 P1148A substitution was initially considered to be a
Marfan syndrome mutation in a mixed population of
patients, because it had not been found in white or Af-
rican American control subjects. However, it was later
found to be a polymorphism in Asians (Wang et al.
1997). The homeo box A1 A218G polymorphism was
reported to increase susceptibility to autism; however, it
was found to be more common in African Americans
than in whites (Collins et al., in press). Thus, one could
misinterpret a negative result if only a single racial or
ethnic group is utilized as a control population.
The sex of the control subjects is of obvious impor-
tance in testing for polymorphisms in X-linked genes.
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Table 1
Sample Sizes Needed to Detect Polymorphisms
Na
Polymorphism
Frequency Alpha Power
40 .05 .05 .80
65 .05 .05 .95
210 .01 .05 .80
340 .01 .05 .95
2,400 .001 .05 .80
3,910 .001 .05 .95
a N signifies the number of chromosomes, and this applies to either
X-linked or autosomal diseases.
Often, the sex of the control subjects used is not men-
tioned in the literature. If one looks at chromosomes
from normal females in X-linked mental retardation
(XLMR), the significance of finding an alteration is un-
clear, because females are not likely to be affected by a
change that could be pathogenic in a male. Therefore,
it is imperative, in studying XLMR, to examine chro-
mosomes solely from males of normal intelligence in a
reference population and to cite this in any publication.
How many normal controls should be analyzed to
detect a 5%, 1%, or 0.1% polymorphism? We used
power calculations performed by the Power and Preci-
sion program (Biostat) to determine the number of chro-
mosomes required to detect a significant difference be-
tween the polymorphism frequency in the reference
population and the expected frequency. The polymor-
phism proportion in the hypothetical control group was
set to 0.001% (as close to 0% as possible), since 0% of
the controls would be expected to carry a disease-causing
mutation. The alpha, or significance level, was set to
5%. The power, or percent of studies expected to yield
a significant effect, was set to both 80% and 95%. Power
is commonly set at 80%; however, at that level, a poly-
morphism would be missed 20% of the time. If a power
of 95% were used, there would be only a 5% possibility
of missing a polymorphism.
Table 1 displays the number of chromosomes that
should be examined to significantly determine if the
polymorphism frequency in the reference population dif-
fers from the expected frequency. The examination of a
minimum of 65 chromosomes is necessary to detect a
5% polymorphism with 95% power. Therefore, 95% of
the time, the polymorphism will be detected if it is in
the population. For a 1% polymorphism, a minimum
of 340 chromosomes should be examined. This number
is close to Marchuk’s (1998) proposal of typing 300–400
or more chromosomes to detect a 1% polymorphism.
Finally, 3,910 chromosomes would be required to detect
a 0.1% polymorphism with 95% power.
These numbers of chromosomes can also be applied
to the search for mutations in disease genes. If each dis-
ease gene has been found to cause a certain percentage
of a disease, one can utilize that information to deter-
mine how many affected individuals should be screened
for mutations. For example, it would appear that each
known XLMR gene accounts for ∼1% of XLMR (Chelly
and Mandel 2001). Therefore, a minimum of 340 un-
related males with XLMR should be tested to detect a
single alteration in any candidate gene with 95% power.
In summary, when a potential mutation is detected,
the status, race, and number of control subjects used for
polymorphism detection need to be carefully considered.
For X-linked conditions, the sex of controls used should
also be taken into consideration. These characteristics
are crucial to formulating accurate results. The sample
sizes in table 1 can also be applied to the identification
of candidate gene mutations in affected individuals.
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